# Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma

> **NCT07654465** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 144 (estimated)

## Conditions studied

- Marginal Zone Lymphoma(MZL)

## Interventions

- **DRUG:** Rituximab
- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT07654465
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2030-07
- **Final completion:** 2031-07
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654465, "Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07654465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*